SEC Form 4
Medifast, Inc. (MED) insider trading
In the 12 months to Oct 24, 2026, one MED insider reported open-market sales of $226.3K across 1 filing; 3 insiders bought $1.7M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $226.3K
- 1 filing · 1 insider
- Open-market purchases
- $1.7M
- 5 filings
- Pre-arranged sales (10b5-1)
- 1 of 1
- All $226.3K sold was pre-arranged
Who traded MED, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
MED daily close from Oct 24, 2025 to Oct 23, 2026, between $9.45 and $13.15, last $11.87. 1 sale and 5 purchase filings by 3 insiders, marked at their filing dates. Parsa Kiai, Director: bought $1.4M across 3 filings, first filed Aug 21, 2026, last Aug 28, 2026. Daniel R. Chard, Chairman & CEO → Director: sold $226.3K and bought $178.7K across 2 filings, first filed Mar 27, 2026, last Sep 30, 2026. Scott Schlackman, Director: bought $63.0K across 1 filing, first filed May 12, 2026, last May 12, 2026.
Largest mark · tap a row for others
Parsa Kiai · Director
Filing 1 of 2 within a week · $894,645 total
Purchase $842,699
72,487 shares at $11.63 avg
Filed Aug 21, 2026 · traded Aug 19
Close on filing date $11.95
Parsa Kiai · Director
Director
$1.4M boughtDaniel R. Chard · Chairman & CEO → Director
Chairman & CEO → Director
$226.3K sold$178.7K boughtScott Schlackman · Director
Director
$63.0K boughtHas Medifast, Inc.'s CEO sold stock?
No. Daniel R. Chard (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
6 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Parsa Kiai | Director | — | $1.4M | 3 | — | |
| Daniel R. Chard | Chairman & CEO → Director | $226.3K | $178.7K | 2 | 100% of sales | |
| Scott Schlackman | Director | — | $63.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Daniel R. Chard Director | SalePre-arranged (10b5-1) | 19,089 | $11.85 | $226.3K | 130,609 | |
traded | Parsa Kiai Director | Purchase | 43,150 | $12.26 | $529.2K | 707,492 | |
traded | Parsa Kiai Director | Purchase | 4,329 | $12.00 | $51.9K | 19,095 | |
traded | Parsa Kiai Director | Purchase | 72,487 | $11.63 | $842.7K | 661,306 | |
traded | Scott Schlackman Director | Purchase | 5,000 | $12.59 | $63.0K | 30,549 | |
traded | Daniel R. Chard Chairman & CEO | Purchase | 17,678 | $10.11 | $178.7K | 17,678 |
GET /stocks/filings/vX/form-4?tickers=MED&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"MED"
],
"issuer_cik": "0000910329",
"owner_cik": "0001289557",
"accession_number": "0001628280-26-064063",
"form_type": "4",
"filing_date": "2026-09-30",
"period_of_report": "2026-09-28",
"issuer_name": "MEDIFAST INC",
"issuer_trading_symbol": "MED",
"owner_name": "Chard Daniel R",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-28",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9545,
"transaction_price_per_share": 11.9788,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 140153.352,
"transaction_value": 114337.646,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "The Dan and Allyson Family Irrevocable Trust",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.900 to $12.125, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
},
{
"id": "F2",
"description": "These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee."
}
]
},
{
"tickers": [
"MED"
],
"issuer_cik": "0000910329",
"owner_cik": "0001289557",
"accession_number": "0001628280-26-064063",
"form_type": "4",
"filing_date": "2026-09-30",
"period_of_report": "2026-09-28",
"issuer_name": "MEDIFAST INC",
"issuer_trading_symbol": "MED",
"owner_name": "Chard Daniel R",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-29",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9544,
"transaction_price_per_share": 11.73,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 130609.352,
"transaction_value": 111951.12000000001,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "The Dan and Allyson Family Irrevocable Trust",
"footnotes": [
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.670 to $11.810, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
},
{
"id": "F2",
"description": "These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 21 records
- Tax withholding9 records
- Grants and awards12 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for MED every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.